Why Moderna stock doubled
On August 19, 2026, Moderna and Merck announced that their personalized mRNA cancer vaccine, given in combination with Merck's immunotherapy Keytruda, met its initial goals in a late-stage melanoma trial. The Phase 3 study enrolled more than 1,100 patients and significantly reduced the recurrence of melanoma versus the standard of care.
The market's answer was one of the most violent single-day repricings of a large-cap stock this year. MRNA closed at $174.38, up $111.42 on the day, a gain of 176.97%. MRK rose 12.61%. The story was corroborated across six outlets within hours, including the FT, Bloomberg, Fortune, Ars Technica, and Fast Company, and you can follow the full sourced timeline on our wire story.
What the trial actually showed
Three details separate this from the usual biotech headline pop:
- It is Phase 3. This is the late-stage, standard-of-care comparison that regulators weigh most heavily, not an early signal in a handful of patients. Coverage of the result described it as setting up an approval push.
- The vaccine is personalized. Each dose is built from an individual patient's tumor profile, the application mRNA bulls have pointed to since the COVID era as the technology's real long-term prize.
- It worked alongside Keytruda. The combination cut the risk of melanoma recurrence in a trial of more than 1,100 patients, per the companies' announcement, extending one of oncology's biggest franchises into a new setting rather than competing with it.
That last point is why this moved two stocks at once. Keytruda is Merck's flagship, and a successful combination gives both companies a stake in the outcome.
The short-seller wipeout
Moderna entered this print as a heavily doubted stock, and the reversal was expensive for the doubters: reporting on the move put short sellers' one-day losses at roughly $4.8 billion. Forced short covering is part of how a positive surprise turns into a 177% day rather than a 40% one; shorts buying to close add fuel on the way up.
That mechanical element cuts both ways. Once covering exhausts itself, the tape has to stand on the fundamentals, and in the first pre-market session after the rally, MRNA traded at $155.30, giving back about 11% from the close. A give-back after a squeeze-amplified move is normal; it is not, on its own, a verdict on the science.
What to watch from here
The trial result revives the bigger thesis that mRNA technology has applications in oncology, not just infectious disease. What it does not yet answer:
- Approval. A Phase 3 win is the setup, not the finish line. The data now goes in front of regulators, and the timeline is theirs.
- Durability of the move. After binary events, the market spends weeks separating the squeeze from the re-rating. Watch where MRNA settles relative to the pre-announcement price rather than the intraday extremes.
- Read-through to the pipeline. If a personalized mRNA vaccine works in melanoma, the same platform logic applies to other tumor types, which is the part of the story that outlives any single trial.
Track it live
- Live quote, chart, and the day's tape: MRNA quote page
- Is the price ahead of the earnings power? MRNA fair value
- The partner's side of the trade: MRK quote page
- Get notified on the next move: set a price or percent-move alert on MRNA and let the tape come to you. On any quote page you can arm an alert for a 3%, 5%, or 10% daily move in one tap.
Prices as of the August 19, 2026 close and the August 20 pre-market session. Trial facts per the Moderna and Merck announcement as reported across the six outlets cited on our wire. This is reporting and analysis, not investment advice.